2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Labcorp company profile · diagnostics & biopharma laboratory services · history · financial snapshot · S&P 500 rank #329 · 拉伯克公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | LH (NYSE) |
| Company | Labcorp Holdings Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Services |
| S&P 500 rank (by weight) | #329 · 0.04% (Nov 2, 2026) |
| Sector rank (by market cap) | #43 in Health Care (Nov 2, 2026) |
| Share price (frozen benchmark) | $359.07 (Nov 2, 2026) |
| Headquarters | Burlington, North Carolina |
| Founded | 1969 (as National Health Laboratories) |
| CEO | Adam Schechter (Chairman and CEO) |
| Employees | nearly 71,000 (FY2025) |
| Market cap | $29.16B (Nov 2, 2026) |
WHAT IT DOES
Labcorp is one of the world's largest laboratory companies, running diagnostic testing for physicians, hospitals and patients, and biopharma laboratory services for drug developers, through a network of laboratories, patient service centers and a large esoteric testing menu.
The model is volume plus menu: routine tests bring scale, while specialty and genetic tests bring price. FY2025 revenue was $13.95B, up 7.2% from $13.01B, GAAP operating income was $1,384.7M, adjusted operating income was $2,001.6M, net earnings attributable were $876.5M, and diluted EPS was $10.46 (adjusted $16.44).
Diagnostics is the anchor: Diagnostics Laboratories revenue was $10,876.5M, up 7.2%, while Biopharma Laboratory Services revenue of $3,075.5M is derived as total revenue minus Diagnostics, up 7.4% on the same derived basis.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Diagnostics Laboratories | $10,876.5M | — | +7.2% |
| Biopharma Laboratory Services | $3,075.5M (derived) | — | +7.4% (derived) |
HISTORY
| Year | Milestone |
|---|---|
| 1969 | National Health Laboratories founded |
| 1995 | Laboratory Corporation of America formed, combining National Health Laboratories and Roche Biomedical Laboratories |
| 2023 | Labcorp Holdings spins off Fortrea, its clinical development business |
| 2025 | FY2025 revenue reaches $13.95B, up 7.2% |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenue | $13.95B (+7.2% YoY) |
| GAAP operating income | $1,384.7M |
| Adjusted operating income (stated separately) | $2,001.6M |
| Net earnings attributable / Diluted EPS | $876.5M / $10.46 (adjusted $16.44) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Labcorp is the S&P 500's diagnostics name: at a 0.04% index weight and #43 in Health Care by market cap, it is the index's main exposure to laboratory testing volumes.
Its test volumes are a standing read on U.S. healthcare utilization — requisition counts move before claims data does.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | Labcorp FY2025 results, release dated Feb 17, 2026 (fiscal year ended Dec 31, 2025), company profile sources |
| Sector classification | GICS (Health Care Services) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | LH(NYSE) |
| 公司 | Labcorp Holdings Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健服務 |
| 標普500排名(按權重) | #329 · 0.04%(2026 年 11 月 2 日) |
| 板塊內排名(按市值) | 醫療保健第 #43(2026 年 11 月 2 日) |
| 股價(凍結基準) | $359.07(2026 年 11 月 2 日) |
| 總部 | 美國北卡羅來納州伯靈頓 |
| 成立 | 1969 年(前身為 National Health Laboratories) |
| 行政總裁 | Adam Schechter(董事長兼行政總裁) |
| 員工 | 近 71,000(FY2025) |
| 市值 | $29.16B(2026 年 11 月 2 日) |
業務概覽
拉伯克是全球最大的實驗室公司之一,透過實驗室、病人服務中心與大型專科檢測項目,為醫生、醫院與病人提供診斷檢測,並為藥物開發商提供生物製藥實驗室服務。
其模式為銷量加項目:常規檢測帶來規模,專科與基因檢測帶來價格。FY2025 收入為 $13.95B,同比增長 7.2%(FY2024 為 $13.01B),GAAP 營業利潤為 $1,384.7M,經調整營業利潤為 $2,001.6M,歸屬淨利潤為 $876.5M,攤薄每股收益為 $10.46(經調整 $16.44)。
診斷是支柱:診斷實驗室收入為 $10,876.5M,同比增長 7.2%;生物製藥實驗室服務收入 $3,075.5M 為總收入減診斷之推算數,同比按同一推算口徑增長 7.4%。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 診斷實驗室 | $10,876.5M | — | +7.2% |
| 生物製藥實驗室服務 | $3,075.5M(推算) | — | +7.4%(推算) |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1969 | National Health Laboratories 創立 |
| 1995 | Laboratory Corporation of America 成立,合併 National Health Laboratories 與 Roche Biomedical Laboratories |
| 2023 | Labcorp Holdings 分拆臨床開發業務 Fortrea |
| 2025 | FY2025 收入達 $13.95B,同比增長 7.2% |
競爭地位
財務快照 — FY2025
| 總收入 | $13.95B(同比 +7.2%) |
| GAAP 營業利潤 | $1,384.7M |
| 經調整營業利潤(分開列示) | $2,001.6M |
| 歸屬淨利潤/攤薄每股收益 | $876.5M/$10.46(經調整 $16.44) |
主要風險
對標普500的重要性
拉伯克是標普500的診斷標的:指數權重 0.04%、醫療保健板塊市值第 #43,是指數對實驗室檢測銷量的主要敞口。
其檢測銷量,是美國醫療使用量的常設讀數——檢測申請數往往先於理賠數據變動。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | 拉伯克 FY2025 業績,2026 年 2 月 17 日公告(財政年度截至 2025 年 12 月 31 日)、公司簡介來源 |
| 板塊分類 | GICS(醫療保健服務),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 13:04 · updated 2026-11-14 23:44 · rev 6